These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26806782)

  • 41. Pharmacotherapy of amphetamine-type stimulant dependence: an update.
    Brensilver M; Heinzerling KG; Shoptaw S
    Drug Alcohol Rev; 2013 Sep; 32(5):449-60. PubMed ID: 23617468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Individual, Social, and Environmental Factors Associated with Different Patterns of Stimulant Use: A Cross-Sectional Study from Five European Countries.
    Rosenkranz M; O'Donnell A; Martens MS; Zurhold H; Degkwitz P; Liebregts N; Barták M; Rowicka M; Verthein U
    Eur Addict Res; 2023; 29(3):182-193. PubMed ID: 37166303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine.
    Stoops WW
    Exp Clin Psychopharmacol; 2006 Nov; 14(4):413-21. PubMed ID: 17115868
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses.
    Rasmussen N
    Int Rev Neurobiol; 2015; 120():9-25. PubMed ID: 26070751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of methamphetamine use disorders: an update.
    Rawson RA; Gonzales R; Brethen P
    J Subst Abuse Treat; 2002 Sep; 23(2):145-50. PubMed ID: 12220612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Increasing prevalence of amphetamine--and methamphetamine-induced psychosis].
    Härtel-Petri R; Rodler R; Schmeisser U; Steinmann J; Wolfersdorf M
    Psychiatr Prax; 2005 Jan; 32(1):13-7. PubMed ID: 15633070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of the GABA system in amphetamine-type stimulant use disorders.
    Jiao D; Liu Y; Li X; Liu J; Zhao M
    Front Cell Neurosci; 2015; 9():162. PubMed ID: 25999814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251.
    Vinklerová J; Nováková J; Sulcová A
    J Psychopharmacol; 2002 Jun; 16(2):139-43. PubMed ID: 12095072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Stimulant-induced adaptations in neostriatal matrix and striosome systems: transiting from instrumental responding to habitual behavior in drug addiction.
    Canales JJ
    Neurobiol Learn Mem; 2005 Mar; 83(2):93-103. PubMed ID: 15721792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Substitution therapy tested against amphetamine dependence].
    Bloniecki Kallio V; Guterstam J; Franck J
    Lakartidningen; 2016 Jan; 113():. PubMed ID: 26756343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.
    Rothman RB; Baumann MH; Dersch CM; Romero DV; Rice KC; Carroll FI; Partilla JS
    Synapse; 2001 Jan; 39(1):32-41. PubMed ID: 11071707
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Amphetamine neurotoxicity: accomplishments and remaining challenges.
    McCann UD; Ricaurte GA
    Neurosci Biobehav Rev; 2004 Jan; 27(8):821-6. PubMed ID: 15019431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DARK Side of Amphetamine and Analogues: Pharmacology, Syndromic Manifestation, and Management of Amphetamine Addiction.
    Baig AM
    ACS Chem Neurosci; 2018 Oct; 9(10):2299-2303. PubMed ID: 29671582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment.
    Volz TJ; Fleckenstein AE; Hanson GR
    Addiction; 2007 Apr; 102 Suppl 1():44-8. PubMed ID: 17493052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influence of a low dose of amphetamine on vesicular monoamine transporter binding: a PET (+)[11C]DTBZ study in humans.
    Boileau I; Houle S; Rusjan PM; Furukawa Y; Wilkins D; Tong J; Selby P; Wilson AA; Kish SJ
    Synapse; 2010 Jun; 64(6):417-20. PubMed ID: 20169578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Governing through problems: the formulation of policy on amphetamine-type stimulants (ATS) in Australia.
    Fraser S; Moore D
    Int J Drug Policy; 2011 Nov; 22(6):498-506. PubMed ID: 22054738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Periadolescent amphetamine treatment causes transient cognitive disruptions and long-term changes in hippocampal LTP depending on the endogenous expression of pleiotrophin.
    Gramage E; Del Olmo N; Fole A; Martín YB; Herradón G
    Addict Biol; 2013 Jan; 18(1):19-29. PubMed ID: 21812875
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Approaches to the development of medications for the treatment of methamphetamine dependence.
    Vocci FJ; Appel NM
    Addiction; 2007 Apr; 102 Suppl 1():96-106. PubMed ID: 17493058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Driving under the influence of amphetamine and metamphetamine].
    Lia K; Spigset O; Slørdal L
    Tidsskr Nor Laegeforen; 2009 Jan; 129(2):105-8. PubMed ID: 19151802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of amphetamine-CNS depressant combinations and of other CNS stimulants in four-choice drug discriminations.
    Li M; Wessinger WD; McMillan DE
    J Exp Anal Behav; 2005 Jul; 84(1):77-97. PubMed ID: 16156138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.